Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer�
Go back to Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer�| (NASDAQ: IONS) | Delayed: 74.68 +0.56 (0.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $74.12 | 52 Week High | $62.68 | |||
| Open | $74.85 | 52 Week Low | $19.59 | |||
| Day High | $75.51 | P/E | N/A | |||
| Day Low | $74.12 | EPS | $0.00 | |||
| Volume | 209,015 | |||||
